Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica

S. S. Wang, M. Schiffman, T. S. Shields, R. Herrero, A. Hildesheim, M. C. Bratti, M. E. Sherman, A. C. Rodriguez, Philip E. Castle, J. Morales, M. Alfaro, T. Wright, S. Chen, B. Clayman, Robert D. Burk, R. P. Viscidi

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Human papillomavirus (HPV) seroprevalence and determinants of seropositivity were assessed in a 10 049-woman population-based cohort in Guanacaste, Costa Rica. Serologic responses based on VLP-based ELISA were obtained from the plasma collected at study enrollment in 1993/1994 for HPV-16 (n = 9949), HPV-18 (n = 9928), HPV-31 (n = 9932), and HPV-45 (n = 3019). Seropositivity was defined as five standard deviations above the mean optical density obtained for studied virgins (n = 573). HPV-1 6, -18, -31, and -45 seroprevalence was 15, 15, 16, and 11%, respectively. Of women DNA-positive for HPV-16, -18, -31, or -45, seropositivity was 45, 34, 51, and 28%, respectively. Peak HPV seroprevalence occurred a decade after DNA prevalence; lifetime number of sexual partners was the key determinant of seropositivity independent of DNA status and age. DNA- and sero-positive women showed the highest risk for concurrent CIN3/cancer, followed by DNA-positive, sero-negative women.

Original languageEnglish (US)
Pages (from-to)1248-1254
Number of pages7
JournalBritish Journal of Cancer
Volume89
Issue number7
DOIs
StatePublished - Oct 6 2003

Fingerprint

Costa Rica
Human papillomavirus 18
Human papillomavirus 16
Seroepidemiologic Studies
DNA
Population
Human papillomavirus 31
Human papillomavirus 6
Sexual Partners
Enzyme-Linked Immunosorbent Assay
Neoplasms

Keywords

  • Cervical cancer
  • HPV
  • Predictors
  • Seroprevalence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wang, S. S., Schiffman, M., Shields, T. S., Herrero, R., Hildesheim, A., Bratti, M. C., ... Viscidi, R. P. (2003). Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica. British Journal of Cancer, 89(7), 1248-1254. https://doi.org/10.1038/sj.bjc.6601272

Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica. / Wang, S. S.; Schiffman, M.; Shields, T. S.; Herrero, R.; Hildesheim, A.; Bratti, M. C.; Sherman, M. E.; Rodriguez, A. C.; Castle, Philip E.; Morales, J.; Alfaro, M.; Wright, T.; Chen, S.; Clayman, B.; Burk, Robert D.; Viscidi, R. P.

In: British Journal of Cancer, Vol. 89, No. 7, 06.10.2003, p. 1248-1254.

Research output: Contribution to journalArticle

Wang, SS, Schiffman, M, Shields, TS, Herrero, R, Hildesheim, A, Bratti, MC, Sherman, ME, Rodriguez, AC, Castle, PE, Morales, J, Alfaro, M, Wright, T, Chen, S, Clayman, B, Burk, RD & Viscidi, RP 2003, 'Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica', British Journal of Cancer, vol. 89, no. 7, pp. 1248-1254. https://doi.org/10.1038/sj.bjc.6601272
Wang, S. S. ; Schiffman, M. ; Shields, T. S. ; Herrero, R. ; Hildesheim, A. ; Bratti, M. C. ; Sherman, M. E. ; Rodriguez, A. C. ; Castle, Philip E. ; Morales, J. ; Alfaro, M. ; Wright, T. ; Chen, S. ; Clayman, B. ; Burk, Robert D. ; Viscidi, R. P. / Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica. In: British Journal of Cancer. 2003 ; Vol. 89, No. 7. pp. 1248-1254.
@article{59102fcacac442eda5077536f67426ca,
title = "Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica",
abstract = "Human papillomavirus (HPV) seroprevalence and determinants of seropositivity were assessed in a 10 049-woman population-based cohort in Guanacaste, Costa Rica. Serologic responses based on VLP-based ELISA were obtained from the plasma collected at study enrollment in 1993/1994 for HPV-16 (n = 9949), HPV-18 (n = 9928), HPV-31 (n = 9932), and HPV-45 (n = 3019). Seropositivity was defined as five standard deviations above the mean optical density obtained for studied virgins (n = 573). HPV-1 6, -18, -31, and -45 seroprevalence was 15, 15, 16, and 11{\%}, respectively. Of women DNA-positive for HPV-16, -18, -31, or -45, seropositivity was 45, 34, 51, and 28{\%}, respectively. Peak HPV seroprevalence occurred a decade after DNA prevalence; lifetime number of sexual partners was the key determinant of seropositivity independent of DNA status and age. DNA- and sero-positive women showed the highest risk for concurrent CIN3/cancer, followed by DNA-positive, sero-negative women.",
keywords = "Cervical cancer, HPV, Predictors, Seroprevalence",
author = "Wang, {S. S.} and M. Schiffman and Shields, {T. S.} and R. Herrero and A. Hildesheim and Bratti, {M. C.} and Sherman, {M. E.} and Rodriguez, {A. C.} and Castle, {Philip E.} and J. Morales and M. Alfaro and T. Wright and S. Chen and B. Clayman and Burk, {Robert D.} and Viscidi, {R. P.}",
year = "2003",
month = "10",
day = "6",
doi = "10.1038/sj.bjc.6601272",
language = "English (US)",
volume = "89",
pages = "1248--1254",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica

AU - Wang, S. S.

AU - Schiffman, M.

AU - Shields, T. S.

AU - Herrero, R.

AU - Hildesheim, A.

AU - Bratti, M. C.

AU - Sherman, M. E.

AU - Rodriguez, A. C.

AU - Castle, Philip E.

AU - Morales, J.

AU - Alfaro, M.

AU - Wright, T.

AU - Chen, S.

AU - Clayman, B.

AU - Burk, Robert D.

AU - Viscidi, R. P.

PY - 2003/10/6

Y1 - 2003/10/6

N2 - Human papillomavirus (HPV) seroprevalence and determinants of seropositivity were assessed in a 10 049-woman population-based cohort in Guanacaste, Costa Rica. Serologic responses based on VLP-based ELISA were obtained from the plasma collected at study enrollment in 1993/1994 for HPV-16 (n = 9949), HPV-18 (n = 9928), HPV-31 (n = 9932), and HPV-45 (n = 3019). Seropositivity was defined as five standard deviations above the mean optical density obtained for studied virgins (n = 573). HPV-1 6, -18, -31, and -45 seroprevalence was 15, 15, 16, and 11%, respectively. Of women DNA-positive for HPV-16, -18, -31, or -45, seropositivity was 45, 34, 51, and 28%, respectively. Peak HPV seroprevalence occurred a decade after DNA prevalence; lifetime number of sexual partners was the key determinant of seropositivity independent of DNA status and age. DNA- and sero-positive women showed the highest risk for concurrent CIN3/cancer, followed by DNA-positive, sero-negative women.

AB - Human papillomavirus (HPV) seroprevalence and determinants of seropositivity were assessed in a 10 049-woman population-based cohort in Guanacaste, Costa Rica. Serologic responses based on VLP-based ELISA were obtained from the plasma collected at study enrollment in 1993/1994 for HPV-16 (n = 9949), HPV-18 (n = 9928), HPV-31 (n = 9932), and HPV-45 (n = 3019). Seropositivity was defined as five standard deviations above the mean optical density obtained for studied virgins (n = 573). HPV-1 6, -18, -31, and -45 seroprevalence was 15, 15, 16, and 11%, respectively. Of women DNA-positive for HPV-16, -18, -31, or -45, seropositivity was 45, 34, 51, and 28%, respectively. Peak HPV seroprevalence occurred a decade after DNA prevalence; lifetime number of sexual partners was the key determinant of seropositivity independent of DNA status and age. DNA- and sero-positive women showed the highest risk for concurrent CIN3/cancer, followed by DNA-positive, sero-negative women.

KW - Cervical cancer

KW - HPV

KW - Predictors

KW - Seroprevalence

UR - http://www.scopus.com/inward/record.url?scp=0242361186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242361186&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6601272

DO - 10.1038/sj.bjc.6601272

M3 - Article

C2 - 14520455

AN - SCOPUS:0242361186

VL - 89

SP - 1248

EP - 1254

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 7

ER -